GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » Equity-to-Asset

Argent Biopharma (ASX:RGT) Equity-to-Asset : 0.08 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Argent Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$1.36 Mil. Argent Biopharma's Total Assets for the quarter that ended in Dec. 2023 was A$17.33 Mil. Therefore, Argent Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.08.

The historical rank and industry rank for Argent Biopharma's Equity-to-Asset or its related term are showing as below:

ASX:RGT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.74   Med: 0.66   Max: 0.93
Current: 0.08

During the past 13 years, the highest Equity to Asset Ratio of Argent Biopharma was 0.93. The lowest was -0.74. And the median was 0.66.

ASX:RGT's Equity-to-Asset is ranked worse than
86.48% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs ASX:RGT: 0.08

Argent Biopharma Equity-to-Asset Historical Data

The historical data trend for Argent Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Equity-to-Asset Chart

Argent Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.39 0.57 0.32 -0.74

Argent Biopharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.32 -0.15 -0.74 0.08

Competitive Comparison of Argent Biopharma's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Equity-to-Asset falls into.



Argent Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Argent Biopharma's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=-7.403/9.984
=-0.74

Argent Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1.356/17.334
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argent Biopharma  (ASX:RGT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Argent Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma (ASX:RGT) Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.

Argent Biopharma (ASX:RGT) Headlines